title: Cetuximab-induced acneiform eruption and the response to isotretinoin.
authors.forename: Pamela
authors.initials: P
authors.lastname: Vezzoli
authors.forename: Angelo Valerio
authors.initials: AV
authors.lastname: Marzano
authors.forename: Franceso
authors.initials: F
authors.lastname: Onida
authors.forename: Elvio
authors.initials: E
authors.lastname: Alessi
authors.forename: Barbara
authors.initials: B
authors.lastname: Galassi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Tomirotti
authors.forename: Emilio
authors.initials: E
authors.lastname: Berti
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003879:Dermatologic Agents / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D066246:ErbB Receptors; D015474:Isotretinoin; D000068818:Cetuximab